Ozempic was designed as a diabetes drug, and its FDA-approved uses go well beyond weight loss. It currently carries three official indications: managing blood sugar in type 2 diabetes, reducing the risk of heart attack and stroke in people with type 2 diabetes and heart disease, and slowing kidney disease progression in people with type 2 diabetes and chronic kidney disease. Beyond those approved uses, researchers are actively studying semaglutide (the active ingredient in Ozempic) for liver disease, polycystic ovary syndrome, alcohol addiction, and even Alzheimer’s disease.
Type 2 Diabetes: The Original Purpose
Ozempic’s primary job is lowering blood sugar. It mimics a natural gut hormone called GLP-1, which tells your pancreas to release more insulin when blood sugar rises after a meal. It also slows digestion, so glucose enters your bloodstream more gradually, and it signals your liver to produce less sugar on its own.
In clinical trials, Ozempic lowered A1C (the three-month average of blood sugar levels) by 1.2 to 2.1 percentage points depending on the dose and what other medications patients were taking. To put that in perspective, an A1C drop of even 1 point significantly reduces the risk of diabetes complications like nerve damage, vision loss, and kidney problems. It’s given as a once-weekly injection at doses of 0.5 mg, 1 mg, or 2 mg, and patients typically start at a low non-therapeutic dose of 0.25 mg for four weeks before gradually increasing.
Heart Attack and Stroke Prevention
For people with type 2 diabetes and existing cardiovascular disease, Ozempic is FDA-approved to reduce the risk of heart attack, stroke, and cardiovascular death. This isn’t a secondary benefit of better blood sugar control. It’s a distinct indication based on dedicated cardiovascular outcome trials.
The SELECT trial, one of the largest studies of semaglutide’s heart effects, found a 20% reduction in major cardiovascular events (heart attack, stroke, or cardiovascular death) over an average of 33 months. In concrete terms, 6.5% of people taking semaglutide experienced one of these events compared to 8% on placebo. The cardiovascular benefits appear to come from multiple mechanisms: reduced inflammation in blood vessel walls, lower blood pressure, and improvements in cholesterol profiles, all on top of better blood sugar regulation.
Slowing Chronic Kidney Disease
In 2025, the FDA added a third approved indication for Ozempic: reducing the risk of kidney failure and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. This was based on the FLOW trial, published in the New England Journal of Medicine, which followed patients with significant kidney impairment.
The results were striking enough that the trial was stopped early. Patients taking semaglutide had a 24% lower risk of major kidney events, a composite that included kidney failure requiring dialysis or transplant, a 50% or greater decline in kidney filtration, and death from kidney or cardiovascular causes. Cardiovascular death alone dropped by 29%. For the roughly 40% of people with type 2 diabetes who develop some degree of kidney disease, this represents a meaningful new layer of protection. The recommended maintenance dose for this indication is 1 mg once weekly.
Liver Disease (MASH)
Metabolic dysfunction-associated steatohepatitis, known as MASH (formerly called NASH), is a progressive liver disease where fat buildup causes inflammation and scarring. It’s closely linked to obesity and insulin resistance, and until recently there were almost no effective drug treatments. In 2025, the FDA approved Wegovy (a higher-dose version of the same semaglutide molecule in Ozempic) for MASH, making it one of very few approved treatments for the condition.
In a phase 3 trial of 800 participants, 63% of those on semaglutide achieved resolution of their liver inflammation without worsening scarring, compared to 34% on placebo. Liver scarring actually improved in 37% of the semaglutide group versus 22% on placebo. While Ozempic itself doesn’t carry a MASH indication on its label, doctors sometimes prescribe it off-label for patients with both type 2 diabetes and liver disease, since the active drug is identical.
Polycystic Ovary Syndrome (PCOS)
PCOS affects roughly 1 in 10 women of reproductive age and is tightly connected to insulin resistance. When the body needs extra insulin to manage blood sugar, that excess insulin pushes the ovaries to overproduce testosterone. The high testosterone then drives symptoms like irregular periods, acne, excess hair growth, and difficulty getting pregnant.
Ozempic isn’t FDA-approved for PCOS, but it’s increasingly prescribed off-label because it targets the root of that hormonal chain reaction. By improving how efficiently cells respond to insulin, it helps break the cycle of high insulin driving high testosterone. Meta-analyses of GLP-1 receptor agonists in women with PCOS show meaningful reductions in insulin resistance, lower total testosterone levels, and improved menstrual regularity. Some research points to a 72% improvement in natural pregnancy rates compared to placebo, with many women achieving spontaneous ovulation within months of starting treatment.
Alcohol and Substance Use
One of the more surprising areas of research involves addiction. GLP-1 receptors exist not just in the gut and pancreas but also in the brain’s reward pathways, the same circuits hijacked by alcohol, nicotine, and other addictive substances. Many patients on Ozempic have reported reduced interest in drinking or smoking, and researchers are now running formal trials to understand why.
An early phase 2 trial registered on ClinicalTrials.gov is testing semaglutide in people with alcohol use disorder, measuring changes in how much alcohol participants consume and their peak blood alcohol levels over eight weeks. The study also tracks “alcohol demand,” essentially how motivated someone is to drink at various price points. These are still early-stage investigations, and no addiction-related indication has been approved. But the biological rationale is strong: if semaglutide dampens the dopamine response that makes substances feel rewarding, it could reduce cravings at a neurological level rather than relying on willpower alone.
Alzheimer’s Disease Research
Semaglutide has completed a phase 3 clinical trial for early Alzheimer’s disease, called the EVOKE trial. The study enrolled people with early-stage cognitive decline and tracked changes in a standardized dementia rating score over two years. Results are being analyzed as of early 2025.
The scientific logic connects back to insulin. The brain relies heavily on insulin signaling to function, and Alzheimer’s is sometimes called “type 3 diabetes” because of how severely insulin processing breaks down in affected brain tissue. GLP-1 receptor agonists like semaglutide cross the blood-brain barrier and may reduce neuroinflammation, improve the brain’s ability to use glucose for energy, and protect neurons from damage. Whether this translates into measurable cognitive benefits in humans is exactly what the EVOKE trial was designed to answer. A companion trial called EVOKE Plus tested semaglutide alongside standard Alzheimer’s medications.
The fact that a diabetes drug made it all the way to phase 3 Alzheimer’s trials reflects how seriously researchers take the connection between metabolic health and brain function. If the results are positive, semaglutide could become relevant to a condition that currently has very few effective treatments.